Latest HIMS Earnings Report Q4 2024

Company Overview

Hims & Hers Health, Inc. (NYSE: HIMS) is a U.S.-based telehealth company founded in 2017, offering a direct-to-consumer platform that connects individuals with licensed healthcare professionals. The company provides a range of health and wellness products and services, including treatments for sexual health, hair loss, dermatology, mental health, and weight management. Customers can access personalized care and prescription medications through the company's digital platform. In the fourth quarter of 2024, Hims & Hers reported revenues of $481 million, nearly doubling from the same period in 2023, and ended the year with 2.2 million subscribers, a 45% increase from the previous year. Despite these gains, the company's stock experienced a significant decline due to concerns over regulatory changes affecting its compounded weight-loss medications.

Latest HIMS Earnings Comparison (Q4 2024)

Historical HIMS Earnings Data

HIMS Earnings Call Summary Q4 2024

Highlights

• Record Revenue Growth: Q4 revenue reached $481M, up 95% YoY, with full-year 2024 revenue hitting $1.5B (+69% YoY).

• Strong Subscriber Growth: Total subscribers grew 45% YoY to over 2.2 million, with more than 55% subscribing to at least one personalized solution.

• Weight Loss Expansion: GLP-1 revenue reached $225M in 2024, with $100M from oral weight loss treatments in just seven months.

• Strategic Acquisitions:

  • Whole Body Lab Testing: Enables personalized diagnostics for heart, hormone, liver, thyroid, and prostate health.

  • Menlo Park Peptide Facility: Strengthens domestic supply chain for innovative metabolic and preventative health treatments.

• AI & Technology Investments: AI-powered MedMatch platform enhances provider efficiency, personalized diagnostics, and follow-up care.

• Super Bowl Ad Impact: Drove strong brand awareness, sparking discussions about healthcare transformation.

• Profitability Milestone: Achieved full-year GAAP profitability for the first time with $126M in net income and $200M in free cash flow.

Risks

1. Regulatory & Legal Uncertainty: FDA restrictions on compounded semaglutide could impact the weight loss business.

2. Competitive Pressure: Increased competition in telehealth, personalized medicine, and GLP-1 treatments.

3. Marketing Efficiency Risks: Despite scaling efforts, marketing as a percentage of revenue remains high (46%).

4. Economic Sensitivity: Consumer spending shifts could impact subscription retention in discretionary health categories.

5. Dependence on Supply Chain: Expansion of sterile fulfillment capabilities and peptide production may face cost and regulatory hurdles.

Opportunities

1. AI-Driven Personalization: Expansion of AI coaches, therapists, nutritionists, and trainers for 24/7 on-demand support.

2. Lab Diagnostics Expansion: New testing capabilities will enable preventative and highly personalized treatments.

3. GLP-1 & Weight Loss Market Leadership: With liraglutide launch expected mid-2025, Hims & Hers is positioned to scale in affordable obesity treatments.

4. Women’s Health Growth: Hers platform now represents 30% of total revenue, driven by dermatology, mental health, and weight loss.

5. New Market Expansion: Plans to enter menopause and low testosterone treatment segments using lab diagnostics.

6. Subscription Growth Path: CEO targets 10 million subscribers within 5–6 years, leveraging AI, personalized treatments, and platform scale.

Outlook

1. 2025 Revenue Guidance: $2.3B–$2.4B, reflecting 56–63% YoY growth.

2. Weight Loss Revenue Target: $725M in 2025, driven by oral weight loss treatments, liraglutide, and personalized GLP-1 solutions.

3. Adjusted EBITDA Growth: Expected to reach $270M–$320M, implying a 13% margin at the midpoint.

4. Marketing Efficiency: Continued focus on reducing marketing as a percentage of revenue by 1–3 points per year.

5. AI & Data Strategy: Long-term vision includes integrating AI-powered tools across diagnosis, treatment, and patient engagement.

6. Investment in Infrastructure: Expansion of Arizona fulfillment center and automation of sterile production to support scalability.

The information is provided for educational purposes only and does not constitute financial advice or recommendation and should not be considered as such. Do your own research.